

DR. HELLA KOHLHOF



Hella Kohlhof is the CSO of Immunic AG in Martinsried, Germany and Managing Director of Immunic's research daughter company, Immunic Research GmbH, Halle (Saale). She joined Immunic in January 2017 from 4SC AG a publicly listed biotech company in Germany where she was responsible for the management of the clinical product portfolio.

Hella Kohlhof studied biology in Aachen, Gothenborg (Sweden) and Munich and received her Doctorate in Biology from the Ludwig Maximilians University of Munich (Germany). During her Ph.D. and PostDoc position at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on the normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling.

In 2008 she joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC's preclinical and clinical stage projects from the oncology and immunology field, including IMU-838 and IMU-366. From 2011 on Hella was responsible for the management and development of 4SC's epigenetic clinical stage small molecule inhibitor 4SC-202.

In early 2015, as Director Development Projects, she took over responsibility for the complete development portfolio of 4SC AG. Hella has a very strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology, clinical trial design and biomarker development.

She has been invited speaker at international conferences and is owner of several patents and co-author of a book chapter and several scientific publications.

SHORT BIO

SKILLS

Transition of preclinical to clinical stage products

EXPERIENCE

Drug development, preclinical and translational pharmacology, clinical trial design, biomarker development

QUALIFICATION

Experienced in preclinical research up to managing the development portfolio at 4SC

MOTIVATION

Developing state-of-the-art treatments of autoimmune diseases